Annual Interest Expense
$78.69 M
+$25.11 M+46.85%
31 December 2023
Summary:
Novo Nordisk A/S annual interest expense is currently $78.69 million, with the most recent change of +$25.11 million (+46.85%) on 31 December 2023. During the last 3 years, it has risen by +$18.93 million (+31.69%). NVO annual interest expense is now -66.76% below its all-time high of $236.74 million, reached on 31 December 2009.NVO Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Interest Expense
$120.99 M
-$104.47 M-46.34%
30 September 2024
Summary:
Novo Nordisk A/S quarterly interest expense is currently $120.99 million, with the most recent change of -$104.47 million (-46.34%) on 30 September 2024. Over the past year, it has dropped by -$195.61 million (-61.78%). NVO quarterly interest expense is now -76.01% below its all-time high of $504.30 million, reached on 30 September 2022.NVO Quarterly Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Interest Expense
$345.33 M
-$195.61 M-36.16%
30 September 2024
Summary:
Novo Nordisk A/S TTM interest expense is currently $345.33 million, with the most recent change of -$195.61 million (-36.16%) on 30 September 2024. Over the past year, it has increased by +$930.70 million (+158.99%). NVO TTM interest expense is now -64.52% below its all-time high of $973.45 million, reached on 30 September 2022.NVO TTM Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVO Interest Expense Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.9% | -61.8% | +159.0% |
| 3 y3 years | +31.7% | -17.7% | +10000.0% |
| 5 y5 years | +484.4% | -2.0% | +22.8% |
NVO Interest Expense High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +71.1% | -76.0% | +111.0% | -64.5% | +159.0% |
| 5 y | 5 years | at high | +484.4% | -76.0% | +111.0% | -64.5% | +159.0% |
| alltime | all time | -66.8% | +1031.3% | -76.0% | +111.0% | -64.5% | +150.7% |
Novo Nordisk A/S Interest Expense History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $120.99 M(-46.3%) | $345.33 M(-36.2%) |
| June 2024 | - | $225.47 M(-25.4%) | $540.94 M(+51.7%) |
| Mar 2024 | - | $302.09 M(-199.6%) | $356.54 M(+64.9%) |
| Dec 2023 | $78.69 M(+46.9%) | -$303.22 M(-195.8%) | $216.26 M(-136.9%) |
| Sept 2023 | - | $316.60 M(+670.9%) | -$585.37 M(+47.2%) |
| June 2023 | - | $41.07 M(-74.6%) | -$397.67 M(-1582.8%) |
| Mar 2023 | - | $161.81 M(-114.6%) | $26.82 M(-67.3%) |
| Dec 2022 | $53.59 M(+16.5%) | -$1.10 B(-319.1%) | $81.94 M(-91.6%) |
| Sept 2022 | - | $504.30 M(+8.3%) | $973.45 M(+58.0%) |
| June 2022 | - | $465.56 M(+114.6%) | $616.11 M(+309.2%) |
| Mar 2022 | - | $216.92 M(-201.7%) | $150.56 M(+139.6%) |
| Dec 2021 | $45.99 M(-23.0%) | -$213.34 M(-245.2%) | $62.83 M(+2076.2%) |
| Sept 2021 | - | $146.97 M(+13.8%) | $2.89 M(-112.2%) |
| Mar 2021 | - | $129.20 M(-147.3%) | -$23.60 M(-160.8%) |
| Dec 2020 | $59.76 M(+81.1%) | -$273.28 M(-723.5%) | $38.82 M(-130.6%) |
| Sept 2020 | - | $43.83 M(-42.8%) | -$126.85 M(+168.8%) |
| June 2020 | - | $76.65 M(-60.0%) | -$47.19 M(-162.9%) |
| Mar 2020 | - | $191.62 M(-143.7%) | $75.06 M(+86.8%) |
| Dec 2019 | $32.99 M(+145.0%) | -$438.95 M(-455.4%) | $40.19 M(-85.7%) |
| Sept 2019 | - | $123.49 M(-37.9%) | $281.32 M(+6.9%) |
| June 2019 | - | $198.89 M(+26.9%) | $263.08 M(+43.3%) |
| Mar 2019 | - | $156.76 M(-179.2%) | $183.56 M(+457.8%) |
| Dec 2018 | $13.46 M(-1.7%) | -$197.83 M(-287.9%) | $32.91 M(-162.3%) |
| Sept 2018 | - | $105.26 M(-11.8%) | -$52.81 M(-66.6%) |
| June 2018 | - | $119.37 M(+1855.7%) | -$158.07 M(+50.1%) |
| Mar 2018 | - | $6.10 M(-102.2%) | -$105.34 M(+2069.4%) |
| Dec 2017 | $13.70 M(+41.8%) | -$283.55 M(-264.7%) | -$4.86 M(-102.1%) |
| June 2017 | - | $172.11 M(+61.5%) | $235.93 M(+269.7%) |
| Mar 2017 | - | $106.58 M(-275.9%) | $63.82 M(+381.0%) |
| Dec 2016 | $9.66 M | -$60.61 M(-439.7%) | $13.27 M(-101.9%) |
| Sept 2016 | - | $17.84 M(-68.2%) | -$681.35 M(+397.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | $56.03 M(-107.4%) | -$136.87 M(-335.7%) |
| Dec 2015 | $9.97 M(+43.3%) | -$755.22 M(-373.7%) | $58.06 M(-91.3%) |
| Sept 2015 | - | $275.95 M(-3.6%) | $668.98 M(+41.9%) |
| June 2015 | - | $286.37 M(+14.1%) | $471.44 M(+123.6%) |
| Mar 2015 | - | $250.97 M(-273.9%) | $210.80 M(+1057.6%) |
| Dec 2014 | $6.96 M(-29.0%) | -$144.31 M(-284.0%) | $18.21 M(-78.3%) |
| Sept 2014 | - | $78.42 M(+204.8%) | $83.87 M(+233.1%) |
| June 2014 | - | $25.73 M(-55.9%) | $25.18 M(-45.5%) |
| Mar 2014 | - | $58.38 M(-174.2%) | $46.23 M(+564.0%) |
| Dec 2013 | $9.79 M(-2.2%) | -$78.65 M(-498.7%) | $6.96 M(-103.6%) |
| Sept 2013 | - | $19.73 M(-57.8%) | -$191.39 M(+51.5%) |
| June 2013 | - | $46.77 M(+144.7%) | -$126.33 M(+399.4%) |
| Mar 2013 | - | $19.11 M(-106.9%) | -$25.30 M(-216.5%) |
| Dec 2012 | $10.02 M(-80.5%) | -$277.00 M(-426.7%) | $21.71 M(-90.3%) |
| Sept 2012 | - | $84.78 M(-42.6%) | $224.11 M(+13.3%) |
| June 2012 | - | $147.81 M(+123.5%) | $197.75 M(+140.7%) |
| Mar 2012 | - | $66.12 M(-188.6%) | $82.17 M(+49.6%) |
| Dec 2011 | $51.37 M(-42.3%) | -$74.60 M(-227.7%) | $54.94 M(-947.9%) |
| Sept 2011 | - | $58.42 M(+81.3%) | -$6.48 M(-136.4%) |
| June 2011 | - | $32.23 M(-17.1%) | $17.79 M(-78.8%) |
| Mar 2011 | - | $38.90 M(-128.6%) | $83.79 M(+3.2%) |
| Dec 2010 | $89.01 M(-62.4%) | -$136.02 M(-264.5%) | $81.16 M(-70.3%) |
| Sept 2010 | - | $82.69 M(-15.8%) | $273.33 M(+18.4%) |
| June 2010 | - | $98.23 M(+170.9%) | $230.79 M(+16.2%) |
| Mar 2010 | - | $36.26 M(-35.4%) | $198.62 M(-15.3%) |
| Dec 2009 | $236.74 M | $56.16 M(+39.9%) | $234.56 M(+31.5%) |
| Sept 2009 | - | $40.15 M(-39.2%) | $178.41 M(+17.7%) |
| June 2009 | - | $66.06 M(-8.5%) | $151.54 M(+77.3%) |
| Mar 2009 | - | $72.20 M(+443.6%) | $85.48 M(-2.0%) |
| Sept 2008 | - | $13.28 M(-82.0%) | $87.25 M(+18.0%) |
| Mar 2008 | - | $73.97 M | $73.97 M |
FAQ
- What is Novo Nordisk A/S annual interest expense?
- What is the all time high annual interest expense for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual interest expense year-on-year change?
- What is Novo Nordisk A/S quarterly interest expense?
- What is the all time high quarterly interest expense for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly interest expense year-on-year change?
- What is Novo Nordisk A/S TTM interest expense?
- What is the all time high TTM interest expense for Novo Nordisk A/S?
- What is Novo Nordisk A/S TTM interest expense year-on-year change?
What is Novo Nordisk A/S annual interest expense?
The current annual interest expense of NVO is $78.69 M
What is the all time high annual interest expense for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual interest expense is $236.74 M
What is Novo Nordisk A/S annual interest expense year-on-year change?
Over the past year, NVO annual interest expense has changed by +$25.11 M (+46.85%)
What is Novo Nordisk A/S quarterly interest expense?
The current quarterly interest expense of NVO is $120.99 M
What is the all time high quarterly interest expense for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly interest expense is $504.30 M
What is Novo Nordisk A/S quarterly interest expense year-on-year change?
Over the past year, NVO quarterly interest expense has changed by -$195.61 M (-61.78%)
What is Novo Nordisk A/S TTM interest expense?
The current TTM interest expense of NVO is $345.33 M
What is the all time high TTM interest expense for Novo Nordisk A/S?
Novo Nordisk A/S all-time high TTM interest expense is $973.45 M
What is Novo Nordisk A/S TTM interest expense year-on-year change?
Over the past year, NVO TTM interest expense has changed by +$930.70 M (+158.99%)